United Therapeutics CEO executes option exercises and open‑market sales totaling 8,000 shares
Rhea-AI Filing Summary
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), reported option exercises and open-market sales under a 10b5-1 plan. On 10/09/2025 and 10/10/2025 she exercised 8,000 stock options with an exercise price of $120.26 each, converting them into 8,000 shares. Concurrently, she sold a total of 8,000 shares in multiple trades at weighted-average prices ranging from $442.96 to $451.24.
After these transactions, Ms. Rothblatt directly owned 130 shares; additional indirect holdings include 324,518, 258,117, 45,596, and 15,962 shares held in various trusts, and 166 shares held indirectly by spouse, reflecting continued substantial family trust ownership and ongoing option tranches expiring 03/15/2026.
Positive
- Use of a pre-arranged 10b5-1 plan provides procedural defense and reduces timing concerns about selective trading
- Exercise of 8,000 options at $120.26 converts in-the-money options to shares, realizing value
- Large indirect holdings in family trusts (totaling over 644,000 shares) show continued substantial ownership and alignment with company interests
Negative
- Direct holdings reduced to 130 shares, which may be perceived as decreased personal equity stake held directly
- 8,000 shares sold in open market could create short-term selling pressure depending on market liquidity
Insights
Insider exercised 8,000 options and sold 8,000 shares via a 10b5-1 plan.
What happened: The reporting person executed exercises of $120.26-strike options (total 8,000) and sold the resulting shares over 10/09/2025–10/10/2025 at weighted-average prices between $442.96 and $451.24.
Dependencies and risks: Transactions were made under a pre-arranged 10b5-1 plan dated 05/02/2025, which limits inference about timing; the plan covers a tranche of 294,000 options expiring 03/15/2026.
Watch for further scheduled exercises or sales under the plan through 12/31/2025 or until the tranche is exhausted.
Substantial indirect family trust ownership remains the dominant shareholding.
After the reported transactions the reporting person directly holds only 130 shares but retains significant indirect positions via trusts totaling over 644,000 shares across named trusts, indicating sustained economic and voting exposure despite recent option exercises and share sales.
This concentration in trusts may influence governance alignment and should be considered when assessing insider alignment and potential voting outcomes in the near term.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,000 | $442.9584 | $443K |
| Sale | Common Stock | 3,000 | $445.2767 | $1.34M |
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,000 | $445.25 | $445K |
| Sale | Common Stock | 2,000 | $449.5825 | $899K |
| Sale | Common Stock | 1,000 | $451.24 | $451K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025. This transaction was executed in multiple trades at prices ranging from $449.335 to $449.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $442.225 to $443.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $445.085 to $446.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
